Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Negative vote for Avastin could have implications for cancer drug approvals

This article was originally published in Scrip

Executive Summary

The strongly negative vote by the FDA's oncologic drugs advisory committee (ODAC) - and an expected FDA decision now to take the extremely rare step of revoking the accelerated approval of Roche's Avastin (bevacizumab) for the treatment of first-line metastatic breast cancer - could have significant implications not only for Roche and the world's best-selling cancer drug but also for future approvals of oncology drugs. The committee members felt that the clinical benefit of Avastin in breast cancer had not been confirmed by the post-marketing studies in the disease.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009636

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel